A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion Parameters in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

Trial Profile

A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Effect of Tadalafil Once Daily for 8 Weeks on Prostatic Blood Flow and Perfusion Parameters in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Aug 2014

At a glance

  • Drugs Tadalafil (Primary)
  • Indications Benign prostatic hyperplasia; Erectile dysfunction; Overactive bladder
  • Focus Pharmacodynamics; Pharmacogenomic; Registrational
  • Acronyms LVIR
  • Sponsors Eli Lilly
  • Most Recent Events

    • 02 Aug 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
    • 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top